Chris Roberts jumps back in­to biotech with CSO gig at Black Di­a­mond; Trou­bled Five Prime ap­points in­ter­im CEO

Chris Roberts Black Di­a­mond

→ Af­ter spend­ing two years as en­tre­pre­neur-in-res­i­dence at SR One — the ven­ture arm of his for­mer em­ploy­er, Glax­o­SmithK­line Chris Roberts is back at the front­lines of biotech.

As CSO of Black Di­a­mond Ther­a­peu­tics, Roberts joins CEO David Ep­stein in dri­ving their tar­get­ed ki­nase in­hibitors to­ward the clin­ic. He will lead re­search and ear­ly de­vel­op­ment on the biotech’s MAP plat­form, which ze­roes in on al­losteric mu­ta­tions of onco­genes. Its lead can­di­date, BDTX-189, tar­gets EGFR and HER2 re­gard­less of tu­mor type.

Can­cer, and par­tic­u­lar­ly ge­net­ic dri­vers of the dis­ease, was some­thing Roberts had some ex­pe­ri­ence with as VP of chem­istry and ear­ly de­vel­op­ment at Sy­ros, where he fo­cused on drug­ging tran­scrip­tion and was cred­it­ed for guid­ing two as­sets in­to clin­i­cal de­vel­op­ment. Be­fore that, he had spear­head­ed in­fec­tious dis­ease projects at GSK and Genelabs

Cam­bridge, MA-based Black Di­a­mond has al­so re­cruit­ed Matt Lu­cas from Yu­man­i­ty Ther­a­peu­tics to lead chem­istry and Tai-An Lin from Mer­ck KGaA to lead bi­ol­o­gy. Its first Phase I/II tri­al is slat­ed for the first half of next year.

Things haven’t been the same for can­cer-fo­cused Five Prime Ther­a­peu­tics, ever since their part­nered drug cabi­ral­izum­ab in com­bi­na­tion with Op­di­vo showed signs of weak ef­fi­ca­cy and a trou­bling safe­ty pro­file in an ear­ly-stage pan­cre­at­ic can­cer study in late 2017. As a re­sult of that fail­ure, the com­pa­ny axed 41 jobs in Jan­u­ary — rough­ly 20% of the com­pa­ny’s work­force — to fo­cus on late-stage pipelines. The South San Fran­cis­co-based com­pa­ny has tapped William “Bill” Ringo as act­ing in­ter­im CEO, suc­ceed­ing Aron Knicker­bock­er “who has re­signed from the com­pa­ny to pur­sue new chal­lenges and op­por­tu­ni­ties.” Cur­rent­ly, Ringo is the chair­man of com­pa­ny’s board of di­rec­tors  — and de­spite his tem­po­rary new role, will re­main in that po­si­tion. Ringo’s past ex­pe­ri­ence in­cludes pres­i­dent and CEO of Ab­genix and gigs at Pfizer and Eli Lil­ly.

Nadir Mah­mood Nkar­ta

→ Af­ter NASH con­tender CymaBay Ther­a­peu­tics re­leased neg­a­tive da­ta back in June show­ing that its lead drug se­ladel­par per­formed worse than a place­bo at a three-month read­out from its on­go­ing 52-week mid-stage study, the com­pa­ny’s stock plum­met­ed about 44.5%. Now, its CMO Pol Boudes is hit­ting the ex­it “to ex­plore oth­er op­por­tu­ni­ties.” Be­fore join­ing CymaBay, Boudes served in the same po­si­tion at Am­i­cus Ther­a­peu­tics and held oth­er stints at Berlex Lab­o­ra­to­ries (lat­er merged with Bay­er Health­Care Phar­ma­ceu­ti­cals), Wyeth-Ay­erst Re­search, Hoff­mann-La Roche and Pas­teur-Merieux Serums & Vac­cines. The com­pa­ny has ini­ti­at­ed a search for a suc­ces­sor. 

→ Fol­low­ing plans to map out clin­i­cal man­u­fac­tur­ing of CAR-NK af­ter a $114 mil­lion Se­ries B round led by Sam­sara ear­li­er this month, Nkar­ta Ther­a­peu­tics has pro­mot­ed Nadir Mah­mood from SVP, cor­po­rate de­vel­op­ment to the new­ly-cre­at­ed po­si­tion of CBO. Mah­mood pre­vi­ous­ly head­ed cor­po­rate de­vel­op­ment at Sec­ond Genome and brings ex­pe­ri­ence from roles at Kythera Bio­phar­ma­ceu­ti­cals (ac­quired by Al­ler­gan) — where he over­saw the pre­clin­i­cal re­search for their lead mol­e­cule, Ky­bel­la — and Gold­man Sachs

An­drew Sto­ber En­cod­ed

→ Back in June, Or­chard Ther­a­peu­tics an­nounced the pric­ing of its IPO — 9 mil­lion Amer­i­can de­posi­tary shares (ADSs) for to­tal gross pro­ceeds of about $128 mil­lion. Now, the UK gene ther­a­py de­vel­op­er has an­nounced that its CCO, Ja­son Meyen­burg is leav­ing the com­pa­ny “to take on a chief ex­ec­u­tive role in the in­dus­try.” Un­til the com­pa­ny can find a per­ma­nent re­place­ment, Mark Rothera, the com­pa­ny’s pres­i­dent and CEO, will as­sume glob­al com­mer­cial lead­er­ship re­spon­si­bil­i­ties. 

→ Gene ther­a­py-fo­cused En­cod­ed Ther­a­peu­tics has ex­pand­ed its lead­er­ship team with the ap­point­ments of An­drew Sto­ber as chief man­u­fac­tur­ing of­fi­cer and David Mc­N­inch as CBO. Sto­ber joins the com­pa­ny af­ter lead­ing gene ther­a­py man­u­fac­tur­ing at No­var­tis and af­ter roles at AveX­is, Bio­gen, Mer­ck and Am­gen. Pre­vi­ous­ly, Mc­N­inch served as chief com­mer­cial of­fi­cer at Prothena and dur­ing his stint at In­ter­Mune he helped or­ga­nize the launch of the first treat­ment for IPF and the com­pa­ny’s lat­er ac­qui­si­tion by Roche. Mc­N­inch al­so spent time at Ipsen, Genen­tech, No­var­tis and As­traZeneca pri­or to his new gig.

David Mc­N­inch En­cod­ed

→ In April, Ever­est Med­i­cines inked a deal with Im­munomedics — mak­ing it one of the top 5 in-li­cens­ing com­pa­nies in Chi­na in the past 11 years. Ever­est is now bol­ster­ing its team with sev­er­al new ap­point­ments. Ja­son Brown, who has been serv­ing as the com­pa­ny’s SVP of busi­ness de­vel­op­ment, has been ap­point­ed to the po­si­tion of CBO. In ad­di­tion to his ap­point­ment, Ever­est has named pre­vi­ous Sanofi ex­ec, Frank Grams, as SVP of al­liance man­age­ment; for­mer Sanofi Chi­na head, Sophia Zhu, as SVP of port­fo­lio de­vel­op­ment and strate­gic plan­ning; Ex-Ab­bott gen­er­al man­ag­er, Alex Wang, as head of in­ter­na­tion­al busi­ness and for­mer head of fi­nance of Am­gen Chi­na, Daniel Weng, as vice pres­i­dent of fi­nance.

Flag­ship-backed Foghorn Ther­a­peu­tics has ex­pand­ed its lead­er­ship with the ap­point­ments of Samuel Agres­ta as CMO and Al­lan Reine as CFO. Agres­ta for­mer­ly served in the same po­si­tion at In­fin­i­ty Phar­ma­ceu­ti­cals — and has worked as vice pres­i­dent and head of clin­i­cal de­vel­op­ment at Agios Phar­ma­ceu­ti­cals, where he over­saw the de­vel­op­ment and reg­is­tra­tion of ivosi­denib (Tib­so­vo) and enasi­denib (Id­hi­fa). Reine hops on board af­ter serv­ing in the same po­si­tion at Pieris Phar­ma­ceu­ti­cals. Stints at Lom­bard Odi­er As­set Man­age­ment, SAC Cap­i­tal Ad­vi­sors and Alexan­dra In­vest­ment Man­age­ment dot Reine’s re­sume.

Salarius Phar­ma­ceu­ti­cals has ap­point­ed Scott Jor­dan on board as CBO and Mark Rosen­blum as ex­ec­u­tive vice pres­i­dent fi­nance and in­ter­im CFO. With these new ad­di­tions, the com­pa­ny can fur­ther op­er­a­tions in its lead clin­i­cal pro­grams in Ew­ing sar­co­ma and ad­vanced sol­id tu­mors to aim at pro­duc­ing po­ten­tial da­ta in 2020. Jor­dan tran­si­tioned to the role af­ter serv­ing as Salarius’ CFO. Pre­vi­ous­ly, he served as CFO at Be­ta Cat Phar­ma­ceu­ti­cals and chief in­vest­ment of­fi­cer at Stingray Ther­a­peu­tics. He’s al­so the co-founder and ad­vi­sor at Health­ios Xchange. Rosen­blum was pre­vi­ous­ly brought on to the com­pa­ny as a fi­nan­cial con­sul­tant to as­sist with the merge with Flex Phar­ma. Pri­or to that role, Rosen­blum served as chair­man and CEO at Ac­tive­Care.

→ Prince­ton, New Jer­sey-based Oys­ter Point Phar­ma has wel­comed Dan Lochn­er as CFO and John Snis­arenko as CCO. Lochn­er joins af­ter a gig as man­ag­ing di­rec­tor at Gold­man Sachs. Snis­arenko hops over to the com­pa­ny fol­low­ing time as group vice pres­i­dent and head of Shire’s (now Take­da) oph­thalmic busi­ness, lead­ing sales for Xi­idra, Lu­cen­tis, Rit­ux­an and Actem­ra.

in­sitro — led by AI star Daphne Koller — has added Matthew Ras­mussen as vice pres­i­dent of da­ta en­gi­neer­ing and Du­ane Valz as gen­er­al coun­sel. Ras­mussen joins the com­pa­ny from Myr­i­ad Ge­net­ics as vice pres­i­dent of soft­ware en­gi­neer­ing and a pre­vi­ous stint at Coun­syl. Valz joins from Zymer­gen — where he served as the com­pa­ny’s first in-house lawyer and gen­er­al coun­sel, help­ing to struc­ture their Se­ries B and C fi­nanc­ings. Valz held pre­vi­ous po­si­tions at Google, Ya­hoo! and Howard Rice Ne­merovs­ki Canady Falk & Rabkin (now com­bined with Arnold & Porter). 

→ Back in Ju­ly, Cel­gene col­lab­o­rat­ed with Nim­bus Ther­a­peu­tics to bag an op­tion for their ‘high­ly prized’ I/O tar­get, an HPK1 in­hibitor pro­gram. Now, Chris­tine Loh has joined Nim­bus as their SVP, head of bi­ol­o­gy af­ter spend­ing time as the vice pres­i­dent of trans­la­tion­al med­i­cine at Kymera Ther­a­peu­tics. Pre­vi­ous­ly, she served as the ex­ec­u­tive di­rec­tor of re­search — fo­cus­ing on he­mo­phil­ia and sick­le cell dis­ease — at Bio­gen spin­out Biover­a­tiv. She has held po­si­tions at Sir­tris, Pfiz­er and ICOS Cor­po­ra­tion

X4 Phar­ma­ceu­ti­cals — which col­lab­o­rat­ed with the Leukemia & Lym­phoma So­ci­ety in May to ac­cel­er­ate the de­vel­op­ment of their lead prod­uct can­di­date ma­vorix­afor for the treat­ment of Walden­ström’s macroglob­u­line­mia — has named one of its orig­i­nal founders, Re­na­to Skerlj, as SVP, re­search and de­vel­op­ment. He draws from his ex­pe­ri­ence as the in­ven­tor of both pler­ix­afor, a stem cell mo­bi­liz­er ap­proved by the FDA in 2008, and er­tapen­em, an an­ti-bac­te­r­i­al ap­proved by the FDA in 2001. Skerlj’s re­sume in­cludes gigs at Lyso­so­mal Ther­a­peu­tics, Gen­zyme and AnorMED

Vi­nee­ta Be­langer Busi­ness Wire

→ Two years af­ter Zosano Phar­ma re­port­ed pos­i­tive Phase III da­ta for its mi­cronee­dle patch sys­tem for de­liv­er­ing an old mi­graine drug — set­ting up a cam­paign to file an NDA — the com­pa­ny has brought on Dushyant Pathak as SVP of busi­ness de­vel­op­ment. Most re­cent­ly, Pathak served as the as­so­ciate vice chan­cel­lor of re­search, in­no­va­tion and tech­nol­o­gy com­mer­cial­iza­tion, as well as the ex­ec­u­tive di­rec­tor of Ven­ture Cat­a­lyst  at Uni­ver­si­ty of Cal­i­for­nia Davis. Pathak brings ex­pe­ri­ence from his times at iP­ier­ian, as CEO and pres­i­dent of Cellex­i­con, founder of Ven­tureEdge and roles at Axys Phar­ma­ceu­ti­cals and Ch­i­ron

→ While their lead drug can­di­date LYR-210 is in Phase II for the treat­ment of chron­ic rhi­nos­i­nusi­tis, ear, nose and throat dis­eases, Lyra Ther­a­peu­tics has added Vi­nee­ta Be­langer as the com­pa­ny’s SVP of clin­i­cal af­fairs. Be­langer most re­cent­ly served as vice pres­i­dent of clin­i­cal af­fairs at Ave­dro and has held po­si­tions at Iron­wood Phar­ma­ceu­ti­cals, Neu­ro­Vi­sion and Al­con.

Pe­ter Catal­i­no has as­sumed a new gig at Ver­tex as SVP, head glob­al mar­ket­ing. He tran­si­tions to the com­pa­ny af­ter time as glob­al busi­ness fran­chise head car­dio-meta­bol­ic med­i­cines at No­var­tis. While at No­var­tis he worked un­der Paul Hud­son — crank­ing out block­buster heart drug En­tresto  and con­tribut­ing to the Akcea-Io­n­is li­cense deal. Pre­vi­ous­ly, Catal­i­no was an as­so­ciate prin­ci­pal at McK­in­sey & Com­pa­ny

→ Last week, Soli­genix brought Jonathan Guar­i­no on board as their SVP and CFO, suc­ceed­ing Karen Krume­ich who hit the ex­it to pur­sue new op­por­tu­ni­ties. This week the com­pa­ny made the ad­di­tion of Mer­ck vet Daniel Ring as vice pres­i­dent of busi­ness de­vel­op­ment and strate­gic plan­ning. Ring brings ex­pe­ri­ence from his time as vice pres­i­dent of busi­ness de­vel­op­ment at Ex­ela Phar­ma Sci­ences and as ex­ec­u­tive di­rec­tor of cor­po­rate li­cens­ing at Mer­ck

Allen Poir­son has hopped to twoXAR as the com­pa­ny’s SVP of bio­phar­ma­ceu­ti­cal busi­ness de­vel­op­ment. Be­fore join­ing the AI-dri­ven com­pa­ny, Poir­son served as a part­ner at Sil­i­con Val­ley-based VC firm Mighty Cap­i­tal. He for­mer­ly served as the CEO of Sony sub­sidiary Sony Biotech­nol­o­gy and held po­si­tions at NASA and Howard Hugh­es Med­ical In­sti­tute

→ Med­ical de­vice com­pa­ny, BioVen­trix, has tapped Pe­dro Mar­ques as vice pres­i­dent of sales for the Eu­ro­pean mar­ket. Mar­ques pre­vi­ous stints in­clude roles as vice pres­i­dent of glob­al ac­cess and clin­i­cal de­vel­op­ment at Medtron­ic and as VP of in­ter­na­tion­al sales for Heart­Ware

Bio­Th­eryX — fo­cused on mul­ti-ki­nase in­hi­bi­tion and tar­get­ed pro­tein degra­da­tion — has wel­comed Al­ler­gan vet Jef­frey Ed­wards to its board of di­rec­tors. Ed­wards spent 22 years at Al­ler­gan — hold­ing sev­er­al roles in­clud­ing EVP, fi­nance and busi­ness de­vel­op­ment and CFO. 

Ted Love, cur­rent pres­i­dent and CEO of Glob­al Blood Ther­a­peu­tics — which re­cent­ly re­ceiv­ing pri­or­i­ty re­view from the FDA for its sick­le cell dis­ease drug — has joined the board of di­rec­tors at Por­to­la Phar­ma­ceu­ti­cals. Love pre­vi­ous­ly worked at Onyx Phar­ma­ceu­ti­cals, Nu­velo, Ther­a­vance and Genen­tech.

→ Cam­bridge-based Verve Ther­a­peu­tics — who is purs­ing a gene-edit­ing ap­proach to coro­nary artery dis­ease — can now count An­drew Geall, as a mem­ber of the com­pa­ny’s sci­en­tif­ic ad­vi­so­ry board. Geall is the vice pres­i­dent of for­mu­la­tions, an­a­lyt­ics and chem­istry at Avid­i­ty Bio­sciences

→  An­a­lysts hate to lose a biotech CFO they’ve come to trust and ad­mire — es­pe­cial­ly if they’re be­ing blind­sided by a sur­prise ex­it. And Alex­ion’s un­ex­pect­ed an­nounce­ment af­ter the mar­ket close on Tues­day that Paul Clan­cy is on his way out — to be re­placed by a strat­e­gy and busi­ness chief they know vir­tu­al­ly noth­ing about — qual­i­fied as a nasty shock for some high-pro­file com­pa­ny ob­servers. 

Arad­hana Sarin

The Q3 re­port will be a joint ef­fort of Clan­cy and his re­place­ment, Arad­hana Sarin, who will then pick up the CFO job as Clan­cy con­tin­ues to ad­vise the com­pa­ny in­to the mid­dle of next year. So what’s up with that? Clan­cy on­ly ar­rived 2 years ago, step­ping in from Bio­gen, where he al­so com­mand­ed lots of re­spect in a spot­light po­si­tion.

His hir­ing was seen as a coup for Alex­ion watch­ers, as CEO Lud­wig Hantson put to­geth­er his new team, re­or­ga­nized the com­pa­ny af­ter a bruis­ing in­ves­ti­ga­tion over ethics vi­o­la­tions, moved to Boston and laid out his ba­sic strat­e­gy on pro­tect­ing the big Soliris fran­chise. Sarin will take over with a lot to prove. And some an­a­lysts are set­ting the bar high. 

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus — chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history,” Hudson said on a call with reporters, according to the Wall Street Journal. “As tough a choice as that is, we’re making that choice.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi

Paul Hud­son promis­es a bright new fu­ture at Sanofi, kick­ing loose me-too drugs and fo­cus­ing on land­mark ad­vances. But can he de­liv­er?

Paul Hudson was on a mission Tuesday morning as he stood up to address Sanofi’s new R&D and business strategy.

Still fresh into the job, the new CEO set out to convince his audience — including the legions of nervous staffers inevitably devoting much of their day to listening in — that the pharma giant is shedding the layers of bureaucracy that had held them back from making progress in the past, dropping the duds in the pipeline and reprioritizing a more narrow set of experimental drugs that were promised as first-in-class or best-in-class.  The company, he added, is now positioned to “go after other opportunities” that could offer a transformational approach to treating its core diseases.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Left top to right: Mark Timney, Alex Denner, Vas Narasimhan. (The Medicines Company, Getty, AP/Endpoints News)

In a play-by-play of the $9.7B Med­Co buy­out, No­var­tis ad­mits it over­paid while of­fer­ing a huge wind­fall to ex­ecs

A month into his tenure at The Medicines Company, new CEO Mark Timney reached out to then-Novartis pharma chief Paul Hudson: Any interest in a partnership?

No, Hudson told him. Not now, at least.

Ten months later, Hudson had left to run Sanofi and Novartis CEO Vas Narasimhan was paying $9.7 billion for the one-drug biotech – the largest in the string of acquisitions Narasimhan has signed since his 2017 appointment.

The deal was the product of an activist investor and his controversial partner working through nearly a year of cat-and-mouse negotiations to secure a deal with Big Pharma’s most expansionist executive. It represented a huge bet in a cardiovascular field that already saw two major busts in recent years and brought massive returns for two of the industry’s most eye-raising names.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

This is the second biotech buyout pact today, marking a brisk tempo of M&A deals in the lead-up to the big JP Morgan gathering in mid-January. It’s no surprise the acquisitions are both for cancer drugs, where Sanofi will try to make its mark while Merck beefs up a stellar oncology franchise. And bolt-ons are all the rage at the major pharma players, which you could also see in Novartis’ recent $9.7 billion MedCo buyout.

ArQule — which comes out on top after their original lead drug foundered in Phase III — highlighted early data on ‘531 at EHA from a group of 6 chronic lymphocytic leukemia patients who got the 65 mg dose. Four of them experienced a partial response — a big advance for a company that failed with earlier attempts.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson. Sanofi

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about.

The French pharma giant announced early Monday that it is snagging San Diego biotech Synthorx in a $2.5 billion deal. That marks an affordable bolt-on for Sanofi but a considerable return for Synthorx backers, including Avalon, RA Capital and OrbiMed: At $68 per share, the price represents a 172% premium to Friday’s closing.

Synthorx’s take on alternative IL-2 drugs for both cancer and autoimmune disorders — enabled by a synthetic DNA base pair pioneered by Scripps professor Floyd Romesberg — “fits perfectly” with the kind of innovation that he wants at Sanofi, Hudson said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

Amgen has signed up to be AbbVie’s neighbor in South San Francisco as it moves into a nine-story R&D facility in the booming biotech hub.

The arrangement gives Amgen 240,000 square feet of space on the Gateway of Pacific Campus, just a few minutes drive from its current digs at Oyster Point. The new hub will open in 2022 and house the big biotech’s Bay Area employees working on cardiometabolic, inflammation and oncology research.

Ab­b­Vie, Scripps ex­pand part­ner­ship, for­ti­fy fo­cus on can­cer drugs

Scripps and AbbVie go way back. Research conducted in the lab of Scripps scientist Richard Lerner led to the discovery of Humira. The antibody, approved by the FDA in 2002 and sold by AbbVie, went on to become the world’s bestselling treatment. In 2018, the drugmaker and the non-profit organization signed a pact focused on developing cancer treatments — and now, the scope of that partnership has broadened to encompass a range of diseases, including immunological and neurological conditions.

South Ko­rea jails 3 Sam­sung ex­ecs for de­stroy­ing ev­i­dence in Bi­o­Log­ics probe

Three Samsung executives in Korea are going to jail.

The convictions came in what prosecutors had billed as “biggest crime of evidence destruction in the history of South Korea”: a case of alleged corporate intrigue that was thrown open when investigators found what was hidden beneath the floor of a Samsung BioLogics plant. Eight employees in total were found guilty of evidence tampering and the three executives were each sentenced to up to two years in prison.